These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 35019778)
1. Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China. Guo Y; Cao Y; Liu H; Yang J; Wang W; Wang B; Li M; Yu F Microbiol Spectr; 2022 Feb; 10(1):e0147521. PubMed ID: 35019778 [TBL] [Abstract][Full Text] [Related]
2. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii. Bakuła Z; Modrzejewska M; Pennings L; Proboszcz M; Safianowska A; Bielecki J; van Ingen J; Jagielski T Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437627 [TBL] [Abstract][Full Text] [Related]
3. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553 [TBL] [Abstract][Full Text] [Related]
4. Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil. de Carvalho LD; de Queiroz Mello FC; Redner P; Campos CED; de Souza Caldas PC; da Silva Lourenço MC; Ramos JP J Glob Antimicrob Resist; 2019 Dec; 19():228-230. PubMed ID: 31100506 [TBL] [Abstract][Full Text] [Related]
5. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment. Zhang Y; Yu C; Jiang Y; Zheng X; Wang L; Li J; Shen X; Xu B Clin Microbiol Infect; 2023 Mar; 29(3):353-359. PubMed ID: 36209990 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of antibiotic resistance in clinical isolates of Narimisa N; Goodarzi F; Bostanghadiri N; Masjedian Jazi F Expert Rev Anti Infect Ther; 2024 Aug; 22(8):669-679. PubMed ID: 38294514 [TBL] [Abstract][Full Text] [Related]
7. Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran. Daneshfar S; Khosravi AD; Hashemzadeh M PLoS One; 2022; 17(8):e0267320. PubMed ID: 35960778 [TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Alcaide F; Calatayud L; Santín M; Martín R Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826 [TBL] [Abstract][Full Text] [Related]
9. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Klein JL; Brown TJ; French GL Antimicrob Agents Chemother; 2001 Nov; 45(11):3056-8. PubMed ID: 11600355 [TBL] [Abstract][Full Text] [Related]
10. Short communication: subtyping of Mycobacterium kansasii by PCR-restriction enzyme analysis of the hsp65 gene. Bakuła Z; Safianowska A; Nowacka-Mazurek M; Bielecki J; Jagielski T Biomed Res Int; 2013; 2013():178725. PubMed ID: 24455675 [TBL] [Abstract][Full Text] [Related]
11. AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin. Burman WJ; Stone BL; Brown BA; Wallace RJ; Böttger EC Diagn Microbiol Infect Dis; 1998 Jun; 31(2):369-71. PubMed ID: 9635911 [TBL] [Abstract][Full Text] [Related]
12. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. Tan Y; Hu Z; Zhao Y; Cai X; Luo C; Zou C; Liu X J Clin Microbiol; 2012 Jan; 50(1):81-5. PubMed ID: 22075601 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880 [TBL] [Abstract][Full Text] [Related]
15. Detection of Mycobacterium kansasii using a combination of loop-mediated isothermal amplification (LAMP) and lateral flow biosensors. Chen C; Lu J; Long B; Rao Z; Gao Y; Wang W; Gao W; Yang J; Zhang S Int Microbiol; 2021 Jan; 24(1):75-82. PubMed ID: 32880033 [TBL] [Abstract][Full Text] [Related]
16. Strain variation amongst clinical and potable water isolates of M. kansasii using automated repetitive unit PCR. Thomson R; Tolson C; Huygens F; Hargreaves M Int J Med Microbiol; 2014 May; 304(3-4):484-9. PubMed ID: 24636860 [TBL] [Abstract][Full Text] [Related]
17. False-positive Gen-Probe direct Mycobacterium tuberculosis amplification test results for patients with pulmonary M. kansasii and M. avium infections. Jorgensen JH; Salinas JR; Paxson R; Magnon K; Patterson JE; Patterson TF J Clin Microbiol; 1999 Jan; 37(1):175-8. PubMed ID: 9854086 [TBL] [Abstract][Full Text] [Related]
18. Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study. Akrami S; Dokht Khosravi A; Hashemzadeh M Pathog Glob Health; 2023 Feb; 117(1):52-62. PubMed ID: 35261334 [TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of Mycobacterium kansasii isolates in the State of São Paulo between 1995-1998. Chimara E; Giampaglia CM; Martins MC; Telles MA; Ueki SY; Ferrazoli L Mem Inst Oswaldo Cruz; 2004 Nov; 99(7):739-43. PubMed ID: 15654431 [TBL] [Abstract][Full Text] [Related]
20. [Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey]. Ceyhan İ; Özkara Ş; Güler MZ; Dulkar G; Altınsoy R; Vezir S Mikrobiyol Bul; 2019 Jul; 53(3):330-335. PubMed ID: 31414634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]